Paper39628785
Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.
Dawson LM and 5 others. Eng Microbiol, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution. Papers, record 39628785. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39628785
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References237
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16507823 | China approves world's first oncolytic virus therapy for cancer treatment. | J Natl Cancer Inst | 2006 | https://conductscience.org/library/papers/16507823 | PubMed |
| 2 | 24374965 | Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. | Mol Ther | 2014 | https://conductscience.org/library/papers/24374965 | PubMed |
| 3 | 35321845 | The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB. | Int J Infect Dis | 2022 | https://conductscience.org/library/papers/35321845 | PubMed |
| 4 | 19373227 | A rapid protocol for construction and production of high-capacity adenoviral vectors. | Nat Protoc | 2009 | https://conductscience.org/library/papers/19373227 | PubMed |
| 5 | 26978385 | A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. | Viruses | 2016 | https://conductscience.org/library/papers/26978385 | PubMed |
| 6 | 28538186 | An Engineered Virus Library as a Resource for the Spectrum-wide Exploration of Virus and Vector Diversity. | Cell Rep | 2017 | https://conductscience.org/library/papers/28538186 | PubMed |
| 7 | 22700462 | Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration. | J Gene Med | 2012 | https://conductscience.org/library/papers/22700462 | PubMed |
| 8 | 10485454 | The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. | Cancer Res | 1999 | https://conductscience.org/library/papers/10485454 | PubMed |
| 9 | 20978378 | Novel adenovirus vector-based vaccines for HIV-1. | Curr Opin HIV AIDS | 2010 | https://conductscience.org/library/papers/20978378 | PubMed |
| 10 | 8892868 | Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. | J Virol | 1996 | https://conductscience.org/library/papers/8892868 | PubMed |
| 11 | 35679480 | In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4. | Blood Adv | 2022 | https://conductscience.org/library/papers/35679480 | PubMed |
| 12 | 22275401 | Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. | J Infect Dis | 2012 | https://conductscience.org/library/papers/22275401 | PubMed |
| 13 | 19390586 | Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. | PLoS One | 2009 | https://conductscience.org/library/papers/19390586 | PubMed |
| 14 | 30047376 | Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). | Lancet | 2018 | https://conductscience.org/library/papers/30047376 | PubMed |
| 15 | 32007145 | Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. | Lancet | 2020 | https://conductscience.org/library/papers/32007145 | PubMed |
| 16 | 33793555 | Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses. | PLoS Negl Trop Dis | 2021 | https://conductscience.org/library/papers/33793555 | PubMed |
| 17 | 22363582 | Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. | PLoS One | 2012 | https://conductscience.org/library/papers/22363582 | PubMed |
| 18 | 36697099 | Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35. | Anticancer Res | 2023 | https://conductscience.org/library/papers/36697099 | PubMed |
| 19 | 6492253 | Adenovirus cyt+ locus, which controls cell transformation and tumorigenicity, is an allele of lp+ locus, which codes for a 19-kilodalton tumor antigen. | J Virol | 1984 | https://conductscience.org/library/papers/6492253 | PubMed |
| 20 | 32826924 | An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. | Nat Commun | 2020 | https://conductscience.org/library/papers/32826924 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39628785
GET https://conductscience.org/api/papers/v1/39628785/references?page=2